About Dr. Fatemeh Ardeshir

Dr. Fatemeh Ardeshir-Larijani serves as an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Board certified in internal medicine, hematology and medical oncology, she specializes in thoracic cancers including lung cancer, mesothelioma, and thymic tumors.

She has particular expertise in thymic epithelial tumors, a rare cancer type that often requires specialized knowledge. These tumors behave differently than other thoracic cancers and respond better to treatment from physicians familiar with their unique characteristics.

Medical Education & Expertise

• Emory Winship Cancer Institute 
• Case Western Reserve School of Medicine (Residency)
• Indiana University School of Medicine (Fellowship)
• Tehran University of Medical Sciences (M.D.)

Associations, Awards & Recognition

• American Society of Clinical Oncology Mentoring Reviewing Program Scholar, ASCO, 2020 (President)

• ASCO Merit Award, 2021
• Board Certified, Hematology
• Board Certified, Internal Medicine
• Board Certified, Medical Oncology

• Career Advancement Award, Binaytara Foundation, 2023
• Career Development Alumni Award, Indiana University, 2021
• Department of Medicine Research Award, Case Western Reserve University, 2019
• Lung Cancer Research Award, Thoracic Surgery Foundation (Co-PI), 2025
• Member, American Association for Cancer Research

• Member, American Society of Clinical Oncology
• Member, International Association for the Study of Lung Cancer’s Rare Tumor Committee 
• Member, International Thymic Malignancy Interest Group 
• Member, Society for Immunotherapy of Cancer

• President, American Society of Clinical Oncology International Medical Graduates Research and Publication Committee
• Young Investigator Award in Translational Research, ECOG-ACRIN, 2023

Why Choose Dr. Ardeshir for Pleural Mesothelioma

A member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute of Emory University, Dr. Ardeshir-Larijani conducts clinical trials focusing on identifying new treatment targets. Her research aims to understand how lung cancers develop resistance to immunotherapy and how to develop effective therapies for patients.

Dr. Ardeshir-Larijani connects patients with experimental therapies at leading cancer centers. Her research expertise directly shapes the treatment approaches she uses with patients, incorporating the latest scientific advances in thoracic oncology.

Publications of Dr. Ardeshir

• F. A-Larijani et al. (2025, October 13). Survival Determinants and Sociodemographic Disparities in Early-Onset Non–Small Cell Lung Cancer. Retrieved from https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2840009
• F. A-Larijani et al. (2025, September 28). AI-based radiomic features predict outcomes and the added benefit of chemoimmunotherapy over chemotherapy in extensive stage small cell lung cancer: A multi-institutional study. Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S0304383525004392?via%3Dihub
• F. A-Larijani et al. (2024, March).  Trop-2 Expression and Its Impact on Survival in Thymic Epithelial Tumors: Brief Report. Retrieved from https://www.clinical-lung-cancer.com/article/S1525-7304(24)00001-9/abstract
• F. A-Larijani et al. (2023, February 14).  Clinicogenomic Landscape of Metastatic Thymic Epithelial Tumors. Retrieved from https://ascopubs.org/doi/10.1200/PO.22.00465
• F. A-Larijani et al. (2022, November). A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139. Retrieved from https://www.clinical-lung-cancer.com/article/S1525-7304(22)00157-7/abstract